SCHEMBL2297677

SCHEMBL2297677

O=C(Nc1ccccc1)C1CNC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.62
MAPT P10636 3/20 0.61
MEN1 O00255 2/20 0.61
KMT2A Q03164 2/20 0.61
GAA P10253 2/20 0.61
GFER P55789 1/20 0.61
GLA P06280 1/20 0.54
POLB P06746 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
KDM4E B2RXH2 1/20 0.51
NPC1 O15118 1/20 0.51
LMNA P02545 1/20 0.51
CASP3 P42574 1/20 0.51
RAB9A P51151 1/20 0.51
SENP7 Q9BQF6 1/20 0.51
DPP4 P27487 1/20 0.51
TDP1 Q9NUW8 1/20 0.50
MC4R P32245 1/20 0.49
YAP1 P46937 1/20 0.49
TEAD4 Q15561 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2987904 0.86 HPGD (0.56) HPGDMAPTMEN1KMT2AGAA
SCHEMBL14505992 0.86 HPGD (0.60) HPGDMAPTMEN1KMT2AGAA
SCHEMBL1318504 0.86 HPGD (0.60) HPGDMAPTMEN1KMT2AGAA
Hydrochloric Acid SCHEMBL1320464 0.84 HPGD (0.58) HPGDMAPTMEN1KMT2AGAA
SCHEMBL2988571 0.84 HPGD (0.54) HPGDMAPTMEN1KMT2AGAA
SCHEMBL1318166 0.83 HPGD (0.66) HPGDMAPTMEN1KMT2AGAA
SCHEMBL1318173 0.83 HPGD (0.66) HPGDMAPTMEN1KMT2AGAA
SCHEMBL2446479 0.83 HPGD (0.66) HPGDMAPTMEN1KMT2AGAA
Hydrochloric Acid SCHEMBL4033476 0.82 HPGD (0.64) HPGDMAPTMEN1KMT2AGAA
SCHEMBL29675219 0.82 GAA (0.85) HPGDMAPTMEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999006-B2 Anticancer agents; mitogen-activated protein kinases (MEK) EXELIXIS, INC. (US) 2011-08-16 US claimed
US-20080166359-A1 Methods of using MEK inhibitors EXELIXIS, INC. 2008-07-10 US claimed
CN-115703765-B Substituted triazole derivative, preparation method, pharmaceutical composition and application thereof 上海赛默罗生物科技有限公司 2025-02-28 CN disclosed
US-20230271955-A1 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2023-08-31 US disclosed
CN-115703765-A Substituted triazole derivative, preparation method, pharmaceutical composition and application thereof 上海赛默罗生物科技有限公司 2023-02-17 CN disclosed
EP-4110781-A1 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Chong Kun Dang Pharmaceutical Corp. (KR) 2023-01-04 EP disclosed
EP-3666770-A1 NOVEL HETEROCYCLIC COMPOUNDS AS CDK8/19 INHIBITORS Joint Stock Company "Biocad" (RU) 2020-06-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271955-A1 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HDAC6, HDAC1, HDAC2 HPGD 1054/4885MAPT 228/4885MEN1 3481/4885
US-20080166359-A1 Methods of using MEK inhibitors BRAF, NRAS, KRAS HPGD 718/4885MAPT 3423/4885MEN1 425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.